伊立替康联合卡铂治疗晚期非小细胞肺癌的临床效果观察.docx

伊立替康联合卡铂治疗晚期非小细胞肺癌的临床效果观察【摘要】目的观察伊立替康（CPT-11）联合卡铂（CBP）方案（IC）治疗晚期非小细胞肺癌（NSCLC）的疗效及不良反应。方法46例经病理学或细胞学确诊的晚期NSCLC患者接受CPT-1150mg/m2d1、8静脉滴注；卡铂按Chatelut公式AUC=5d1静脉滴注21d为1个周期。至少化疗2个周期后评价客观反应率、疾病控制、无进展生存、总生存及不良反应。结果全组部分缓解（PR）16例病情稳定（SD）12例疾病进展（PD）18例有效率（RR）34.8%疾病控制率（DCR）60.9%中位无进展生存时间（PFS）5.8个月中位总生存时间（OS）11.6个月主要不良反应为3～4级粒细胞减少、血小板减少、恶心呕吐、迟发型腹泻、脱发。结论CPT-11联合CBP治疗NSCLC疗效确切患者对不良反应耐受性较好。【关键词】晚期非小细胞肺癌；伊立替康；卡铂DOI：10.14163/ki.11-5547/r.2016.04.001Observationofclinicaleffectbyirinotecancombinedwithcarboplatininthetreatmentofadvancednon-smallcelllungcancerZHANGJianSHAOLi-hua.DepartmentofMedicalOncologyLiaoningDandongCityHospitalofTraditionalChineseMedicineDandong118000China【Abstract】ObjectiveToobservecurativeeffectandadversereactionsbyirinotecan（CPT-11）combinedwithcarboplatin（CBP）solution（IC）inthetreatmentofadvancednon-smallcelllungcancer（NSCLC）.MethodsAtotalof46patientswithpathologicallyorcytologicallydiagnosedadvancedNSCLCreceivedCPT-1150mg/m2d1、8throughintravenousdripandcarboplatinbyChatelutformulaAUC=5d1throughintravenousdrip.Thetreatmentlastedfor21das1course.After2coursesofchemotherapyobjectiveresponseratediseasecontrolrateprogression-freesurvivaltotalsurvivalandadversereactionswereevaluated.ResultsTherewere16partialremission（PR）cases12stabledisease（SD）casesand18progressivedisease（PD）cases.Reaponseratewas34.8%diseasecontrolrate（DCR）was60.9%medianprogression-freesurvival（PFS）timewas5.8monthsandmedianoverallsurvival（OS）timewas11.6months.Mainadversereactionsincludedgrade3～4granulocytopeniathrombocytopenianauseaemesisdiarrheaandalopecia.ConclusionCombinationofCPT-11andCBPprovidespreciseeffectintreatingNSCLCwithgoodtoleranceofadversereactionsinpatients.【Keywords】Advancednon-smallcelllungcancer；Irinotecan；Carboplat